Basilea's Toctino (alitretinoin) receives marketing authorization in Finland

17-Oct-2008 - Finland

Basilea Pharmaceutica Ltd. announces that Toctino® (alitretinoin), a new once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to potent topical corticosteroids, has been approved by Finland's National Agency for Medicines (NAM).

Following the recommendation for regulatory approval under the European decentralized procedure, Toctino® received national regulatory approval in Finland. Following the regulatory approval of Toctino® in Finland, Basilea will submit a pricing and reimbursement dossier to the Finnish authorities.

Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema are also under regulatory review in Canada and in Switzerland.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances